Streetbeat News

Stock Prices

INTR

Goldman Sachs has reaffirmed its Buy rating on Inter & Co (NASDAQ:INTR), raising the price target from $5.80 to $6.50. Despite a slight decline in share price over the last 24 hours, the new target suggests a potential 18.61% increase. Inter & Co, a digital bank, earns most of its revenue from its Banking & Spending segment.

Portfolio Pulse from Benzinga Insights

February 09, 2024 | 5:00 pm

LSPD

Piper Sandler has maintained its Neutral rating on Lightspeed Commerce (NYSE:LSPD) but reduced its price target from $20.00 to $18.00. Despite this, LSPD shares have risen 1.35% in the last 24 hours to $15.00. An increase to the new target price would represent a 20% gain. Lightspeed Commerce offers an omni-channel commerce-enabling SaaS platform, primarily generating revenue from the U.S.

Portfolio Pulse from Benzinga Insights

February 09, 2024 | 5:00 pm

DELL

Dell Technologies's (NYSE:DELL) short interest has decreased by 10.5% since the last report, with 8.80 million shares sold short, representing 3.41% of its float. This decrease in short interest could indicate a more bullish sentiment towards DELL among traders. Compared to its peers, DELL has a lower short interest percentage of float, with the average for its peer group being 7.00%.

Portfolio Pulse from Benzinga Insights

February 09, 2024 | 5:00 pm

KPRX

HC Wainwright & Co. has maintained its Buy rating for Kiora Pharmaceuticals (NASDAQ:KPRX) and increased its price target from $3.50 to $2.00. Despite a recent 0.84% decrease in share price to $0.66, the new target suggests a potential 202.57% increase. Kiora Pharmaceuticals is a clinical-stage company focusing on eye disease treatments.

Portfolio Pulse from Benzinga Insights

February 09, 2024 | 5:00 pm

NYCB

New York Community's (NYSE:NYCB) short interest has decreased by 10.72%, now standing at 25.93 million shares or 4.08% of its float. This decline suggests a more bullish sentiment among investors compared to its peers, with an average short interest of 5.54%. The current short interest represents a 3.45-day average cover time based on trading volume.

Portfolio Pulse from Benzinga Insights

February 09, 2024 | 5:00 pm

TRI

RBC Capital has maintained its Sector Perform rating for Thomson Reuters (NYSE:TRI) and increased its price target from $149.00 to $153.00. Despite this, Thomson Reuters' shares are currently trading at $155.93, indicating a potential 1.88% decline if the price target is met. Thomson Reuters, known for its significant segments in legal professionals, tax and accounting, and corporates, emerged from a $17.6 billion merger and sold Refinitiv to LSE Group in 2021.

Portfolio Pulse from Benzinga Insights

February 09, 2024 | 5:00 pm

INBS

Intelligent Bio Solutions Inc. (NASDAQ:INBS) shares surged after reporting a significant increase in revenue for Q2 and the first six months of the fiscal year, attributed to the acquisition of Intelligent Fingerprinting Ltd. and growth in the Asia Pacific region. Revenue from sales of goods jumped 114% year-over-year for the quarter and 337% for the six months ended Dec. 31, 2023. The company's CEO highlighted substantial growth in product sales and global expansion. A high short interest of 45.66% in INBS shares, coupled with heavy trading volume, may be fueling the stock's sharp rise.

Portfolio Pulse from Erica Kollmann

February 09, 2024 | 4:57 pm

AVGO

MRVL

NVDA

Nvidia Corp's expansion into custom AI chip design challenges Broadcom Inc and Marvell Technology in the custom silicon market. Nvidia's new business unit targets cloud computing and AI applications, leveraging its 80% market share in high-end AI chips. This strategic move, responding to tech giants like OpenAI, Microsoft, Alphabet, and Meta developing in-house chips, could impact Broadcom and Marvell's sales in the $30 billion data center silicon design market. Broadcom and Marvell stocks traded lower following the report.

Portfolio Pulse from Anusuya Lahiri

February 09, 2024 | 4:50 pm

INBS

Intelligent Bio Solutions' stock is trading higher following the announcement of their Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

February 09, 2024 | 4:47 pm

TAK

Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced positive Phase 2b trial results for TAK-861, an oral therapy for narcolepsy type 1 (NT1), showing significant improvements in wakefulness. The company plans to initiate global Phase 3 trials in NT1 in the first half of fiscal year 2024 but will not advance TAK-861 in narcolepsy type 2 (NT2). TAK-861 was safe and well tolerated, with no serious adverse events reported. Takeda's Q3 2023 core net profit was down 9.4%. TAK shares rose 1.29% to $14.18.

Portfolio Pulse from Vandana Singh

February 09, 2024 | 4:46 pm